Celebrex Gets Thumbs Up For Kids, But Cmte. Wants Follow-Up
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Arthritis Advisory Committee urges Pfizer to create an active surveillance program to track potential safety issues from the use of the COX-2 inhibitor for juvenile rheumatoid arthritis.